Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: A bridge between HIV-associated neurologic disorders and drug abuse

American Journal of Pathology

Volumn 175, Issue 3, 2009, Pages 1148-1159

  Gaskill, Peter J ^a   Calderon, Tina M ^a   Luers, Aimée J ^a   Eugenin, Eliseo A ^a   Javitch, Jonathan A ^b   Berman, Joan W ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; MITOGEN ACTIVATED PROTEIN KINASE 3; QUINPIROLE;

ARTICLE; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ABUSE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MACROPHAGE; NEUROPATHOLOGY; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 70349237001     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.081067     Document Type: Article

References (75)

1. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, Wiley CA: Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992, 42:1736-1739
2. Gartner S, Liu Y: Insights into the role of immune activation in HIV neuropathogenesis. J Neurovirol 2002, 8:69-75 (Pubitemid 34520888)
3. Williams KC, Hickey WF: Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 2002, 25:537-562
4. Anthony IC, Bell JE: The neuropathology of HIV/AIDS. Int Rev Psychiatry 2008, 20:15-24
5. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ: Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. Aids 1999, 13:1249-1253 (Pubitemid 29361096)
6. Thomas SA: Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 2004, 10:1313-1324 (Pubitemid 38568084)
7. Peluso R, Haase A, Stowring L, Edwards M, Ventura P: A Trojan Horse mechanism for the spread of visna virus in monocytes. Virology 1985, 147:231-236 (Pubitemid 16200589)
8. Buckner C, Luers A, Calderon T, Eugenin E, Berman J: Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on NeuroAIDS. J NeuroImmune Pharmacol 2006, 1:160-181 (Pubitemid 44257491)
9. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW: CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and neuroAIDS. J Neurosci 2006, 26:1098-1106 (Pubitemid 43237041)
10. Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, Major EO, Nath A, Berman JW: Mechanisms of leukocyte trafficking into the CNS. J Neurovirol 2000, 6(Suppl 1):S82-S85
11. Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, deBakker C, Alvarez X, Lackner AA: Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 2001, 193:905-915 (Pubitemid 32525863)
12. Vazeux R: AIDS encephalopathy and tropism of HIV for brain monocytes/macrophages and microglial cells. Pathobiology 1991, 59:214-218
13. Anderson E, Zink W, Xiong H, Gendelman HE: HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr 2002, 31(Suppl 2):S43-S54 (Pubitemid 35190558)
14. Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R: Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 2005, 111:194-213 (Pubitemid 40909736)
15. Aquaro S, Ronga L, Pollicita M, Antinori A, Ranazzi A, Perno CF: Human immunodeficiency virus infection and acquired immunodeficiency syndrome dementia complex: role of cells of monocyte-macrophage lineage, J Neurovirol 2005, 11(Suppl 3):58-66
16. Davies J, Everall IP, Weich S, McLaughlin J, Scaravilli F, Lantos PL: HIV-associated brain pathology in the United Kingdom: an epidemiological study. AIDS 1997, 11:1145-1150 (Pubitemid 27273612)
17. Nath A, Maragos WF, Avison MJ, Schmitt FA, Berger JR: Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol 2001, 7:66-71 (Pubitemid 32904361)
18. Ferris MJ, Mactutus CF, Booze RM: Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev 2008, 32:883-909
19. Burdo TH, Katner SN, Taffe MA, Fox HS: Neuroimmunity, drugs of abuse, and neuroAIDS. J Neuroimmune Pharmacol 2006, 1:41-49
20. Nath A, Hauser KF, Wojna V, Booze RM, Maragos W, Prendergast M, Cass W, Turchan JT: Molecular basis for interactions of HIV and drugs of abuse, J Acquir Immune Defic Syndr 2002, 31(Suppl 2):S62-S69 (Pubitemid 35190560)
21. Roth MD, Tashkin DP, Choi R, Jamieson BD, Zack JA, Baldwin GC: Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis 2002, 185:701-705 (Pubitemid 34171478)
22. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I: Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 2003, 188:1820-1826 (Pubitemid 38064866)
23. Dhillon NK, Williams R, Peng F, Tsai YJ, Dhillon S, Nicolay B, Gadgil M, Kumar A, Buch SJ: Cocaine-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia. J Neurovirol 2007, 13:483-495
24. Liang H, Wang X, Chen H, Song L, Ye L, Wang SH, Wang YJ, Zhou L, Ho WZ: Methamphetamine enhances HIV infection of macrophages. Am J Pathol 2008, 172:1617-1624 (Pubitemid 351793354)
25. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG: Dopamine receptors: from structure to function. Physiol Rev 1998, 78:189-225
26. Bradberry CW: Acute and chronic dopamine dynamics in a nonhuman primate model of recreational cocaine use. J Neurosci 2000, 20:7109-7115
27. Luscher C, Ungless MA: The mechanistic classification of addictive drugs. PLoS Med 2006, 3:e437
28. Pierce RC, Kumaresan V: The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 2006, 30:215-238
29. Kreek MJ: Cocaine, dopamine and the endogenous opioid system. J Addict Dis 1996, 15:73-96
30. Koob GF, Bloom FE: Cellular and molecular mechanisms of drug dependence. Science 1988, 242:715-723 (Pubitemid 18276493)
31. Talloczy Z, Martinez J, Joset D, Ray Y, Gacser A, Toussi S, Mizushima N, Nosanchuk J, Goldstein H, Loike J, Sulzer D, Santambrogio L: Methamphetamine inhibits antigen processing, presentation, and phagocytosis. PLoS Pathog 2008, 4:e28 (Pubitemid 351340699)
32. Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D: Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci 2001, 21:5916-5924 (Pubitemid 32737724)
33. Di Chiara G, Imperato A: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988, 85:5274-5278 (Pubitemid 18192948)
34. Jones SR, Garris PA, Wightman RM: Different effects of cocaine and nomifensine on dopamine uptake in the caudate-putamen and nucleus accumbens. J Pharmacol Exp Ther 1995, 274:396-403
35. Moghaddam B, Bunney BS: Differential effect of cocaine on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens: comparison to amphetamine. Synapse 1989, 4:156-161 (Pubitemid 19230123)
36. Pontieri FE, Tanda G, Di Chiara G: Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995, 92:12304-12308
37. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D, Moots RJ: Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 2002, 132:34-40 (Pubitemid 35333323)
38. Kirillova GP, Hrutkay RJ, Shurin MR, Shurin GV, Tourkova IL, Vanyukov MM: Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays. J Neurosci Methods 2008, 174:272-280
39. Santambrogio L, Lipartiti M, Bruni A, Dal Toso R: Dopamine receptors on human T- and B-lymphocytes. J Neuroimmunol 1993, 45:113-119
40. Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumder J, Bhattacharya D, Dasgupta PS: Dopamine inhibits cytokine release and expression of tyrosine kinases. Lck and Fyn in activated T cells. Int Immunopharmacol 2003, 3:1019-1026
41. Levite M, Chowers Y, Ganor Y, Besser M, Hershkovits R, Cahalon L: Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. Eur J Immunol 2001, 31:3504-3512 (Pubitemid 34030963)
42. Czub S, Czub M, Koutsilieri E, Sopper S, Villinger F, Muller JG, Stahl-Hennig C, Riederer P, Ter Meulen V, Gosztonyi G: Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. Acta Neuropathol (Berl) 2004, 107:216-226 (Pubitemid 38263411)
43. Czub S, Koutsilieri E, Sopper S, Czub M, Stahl-Hennig C, Muller JG, Pedersen V, Gsell W, Heeney JL, Gerlach M, Gosztonyi G, Riederer P, ter Meulen V: Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol (Berl) 2001, 101:85-91 (Pubitemid 32124479)
44. Bolan EA, Kivell B, Jaligam V, Oz M, Jayanthi LD, Han Y, Sen N, Urizar E, Gomes I, Devi LA, Ramamoorthy S, Javitch JA, Zapata A, Shippenberg TS: D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol 2007, 71:1222-1232 (Pubitemid 46661542)
45. Martin-Negrier ML, Charron G, Bloch B: Receptor recycling mediates plasma membrane recovery of dopamine D1 receptors in dendrites and axons after agonist-induced endocytosis in primary cultures of striatal neurons. Synapse 2006, 60:194-204 (Pubitemid 44036714)
46. Pedrosa R, Soares-da-Silva P: Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br J Pharmacol 2002, 137:1305-1313 (Pubitemid 36071748)
47. Guo W, Shi L, Javitch JA: The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J Biol Chem 2003, 278:4385-4388 (Pubitemid 36800928)
48. Sacerdote P, Martucci C, Vaccani A, Bariselli F, Panerai AE, Colombo A, Parolaro D, Massi P: The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 2005, 159:97-105 (Pubitemid 40126181)
49. Gomez F, Ruiz P, Briceno F, Rivera C, Lopez R: Macrophage Fc-gamma receptors expression is altered by treatment with dopaminergic drugs. Clin Immunol 1999, 90:375-387 (Pubitemid 29159623)
50. Coutinho-Silva R, Ojcius DM, Gorecki DC, Persechini PM, Bisaggio RC, Mendes AN, Marks J, Burnstock G, Dunn PM: Multiple P2X and P2Y receptor subtypes in mouse J774, spleen and peritoneal macrophages. Biochem Pharmacol 2005, 69:641-655
51. Carvalho-Freitas MI, Rodrigues-Costa EC, Nasello AG, Palermo-Neto J, Felicio LF: In vitro macrophage activity: biphasic effect of prolactin and indirect evidence of dopaminergic modulation. Neuroimmunomodulation 2008, 15:131-139
52. Sarkar C, Das S, Chakroborty D, Chowdhury UR, Basu B, Dasgupta PS, Basu S: Cutting Edge: stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J Immunol 2006, 177:7525-7529 (Pubitemid 44846267)
53. Gosztonyi G, Schmidt V, Nickel R, Rothschild MA, Camacho S, Siegel G, Zill E, Pauli G, Schneider V: Neuropathologic analysis of postmortal brain samples of HIV-seropositive and -seronegative i.v. drug addicts. Forensic Sci Int 1993, 62:101-105 (Pubitemid 23346535)
54. Goodkin K, Shapshak P, Metsch LR, McCoy CB, Crandall KA, Kumar M, Fujimura RK, McCoy V, Zhang BT, Reyblat S, Xin KQ, Kumar AM: Cocaine abuse and HIV-1 infection: epidemiology and neuropathogenesis. J Neuroimmunol 1998, 83:88-101 (Pubitemid 28280955)
55. Bowyer JF, Ali S: High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 2006, 60:521-532
56. Nestler EJ: Is there a common molecular pathway for addiction? Nat Neurosci 2005, 8:1445-1449
57. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Miyoshi K, Ogawa N: Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Res 2004, 1029:120-123 (Pubitemid 39463314)
58. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R: Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 1991, 82:39-44
59. Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE, Pearlson GD: Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 1993, 43:2099-2104
60. Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, Bell J, Hauser KF, Mattson M: Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 2000, 14:222-227 (Pubitemid 30847802)
61. Fujimura RK, Goodkin K, Petito CK, Douyon R, Feaster DJ, Concha M, Shapshak P: HIV-1 proviral DNA load across neuroanatomic regions of individuals with evidence for HIV-1-associated dementia. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:146-152 (Pubitemid 27519926)
62. Navia BA, Cho ES, Petito CK, Price RW: The AIDS dementia complex: II. Neuropathology. Ann Neurol 1986, 19:525-535
63. King JE, Eugenin EA, Buckner CM, Berman JW: HIV tat and neurotoxicity. Microbes Infect 2006, 8:1347-1357
64. McManus CM, Weidenheim K, Woodman SE, Nunez J, Hesselgesser J, Nath A, Berman JW: Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein. Tat, and chemokine autoregulation. Am J Pathol 2000, 156:1441-1453 (Pubitemid 30660019)
65. D'Aversa TG, Eugenin EA, Berman JW: NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. J Neurosci Res 2005, 81:436-446
66. Theodore S, Cass WA, Nath A, Maragos WF: Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Curr HIV Res 2007, 5:301-313 (Pubitemid 46785066)
67. Flora G, Lee YW, Nath A, Hennig B, Maragos W, Toborek M: Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp Neurol 2003, 179:60-70 (Pubitemid 36062619)
68. Theodore S, Stolberg S, Cass WA, Maragos WF: Human immunodeficiency virus-1 protein tat and methamphetamine interactions. Ann NY Acad Sci 2006, 1074:178-190 (Pubitemid 44532823)
69. Rohr O, Sawaya BE, Lecestre D, Aunis D, Schaeffer E: Dopamine stimulates expression of the human immunodeficiency virus type 1 via NF-kappaB in cells of the immune system. Nucleic Acids Res 1999, 27:3291-3299 (Pubitemid 29381322)
70. Scheller C, Sopper S, Jassoy C, ter Meulen V, Riederer P, Koutsilieri E: Dopamine activates HIV in chronically infected T lymphoblasts. J Neural Transm 2000, 107:1483-1489
71. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M: Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 2005, 67:1697-1704
72. Seeman P, Van Tol HH: Dopamine receptor pharmacology. Trends Pharmacol Sci 1994, 15:264-270
73. Svenningsson P, Le Moine C: Dopamine D1/5 receptor stimulation induces c-fos expression in the subthalamic nucleus: possible involvement of local D5 receptors. Eur J Neurosci 2002, 15:133-142 (Pubitemid 35478016)
74. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Muller CE, Fisone G, Lluis C, Agnati LF, Franco R, Fuxe K: Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers: a combined neurochemical and behavioral analysis. Neuropharmacology 2008, 54:815-823
75. So CH, Verma V, O'Dowd BF, George SR: Desensitization of the dopamine D1 and D2 receptor hetero-oligomer mediated calcium signal by agonist occupancy of either receptor. Mol Pharmacol 2007, 72:450-462 (Pubitemid 47124125)